Janssen picks up AC Immune's Alzheimer's vaccine
This article was originally published in Scrip
AC Immune has signed a license agreement with Johnson and Johnson subsidiary Janssen, worth a potential $509m, to develop its Alzheimer's disease vaccine candidates.
You may also be interested in...
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Phase I results for Araclon Biotech's Alzheimer's disease vaccine, ABvac40 – the only vaccine data presented at this year's Alzheimer's Association International Conference – warrant further exploration of this innovative approach to the disease.
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.